title: Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases.
abstract: Internationally approved guidelines for the diagnosis and management of Malassezia-related skin diseases are lacking. Therefore, a panel of experts consisting of dermatologists and a microbiologist under the auspices of the Danish Society of Dermatology undertook a data review and compiled guidelines for the diagnostic procedures and management of pityriasis versicolor, seborrhoeic dermatitis and Malassezia folliculitis. Main recommendations in most cases of pityriasis versicolor and seborrhoeic dermatitis include topical treatment which has been shown to be sufficient. As first choice, treatment should be based on topical antifungal medication. A short course of topical corticosteroid or topical calcineurin inhibitors has an anti-inflammatory effect in seborrhoeic dermatitis. Systemic antifungal therapy may be indicated for widespread lesions or lesions refractory to topical treatment. Maintenance therapy is often necessary to prevent relapses. In the treatment of Malassezia folliculitis systemic antifungal treatment is probably more effective than topical treatment but a combination may be favourable.
authors.affiliation: Department of Dermatology, Bispebjerg University Hospital, DK-2400 Copenhagen NV, Denmark. marianne_hald@dadlnet.dk, marianne.hald.01@regionh.dk.
authors.forename: Marianne
authors.initials: M
authors.lastname: Hald
authors.forename: Maiken C
authors.initials: MC
authors.lastname: Arendrup
authors.forename: Else L
authors.initials: EL
authors.lastname: Svejgaard
authors.forename: Rune
authors.initials: R
authors.lastname: Lindskov
authors.forename: Erik K
authors.initials: EK
authors.lastname: Foged
authors.forename: Ditte Marie L
authors.initials: DM
authors.lastname: Saunte
mesh_terms: D000279:Administration, Cutaneous; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D065095:Calcineurin Inhibitors / Q000008:administration & dosage; D012628:Dermatitis, Seborrheic / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D003880:Dermatology / Q000592:standards*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine / Q000592:standards*; D005499:Folliculitis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008290:Malassezia / Q000302:isolation & purification*; D013997:Time Factors; D014010:Tinea Versicolor / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D065095:Calcineurin Inhibitors